Free tool
FAERS Monitor: Orfadin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021232 or its brand name (Orfadin, Nitisinone). Reports on generic versions are filed under their own applications.
Reports
820
Serious
649
79% of reports
Hospitalization
266
Death reported
146
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- amino acid level increased128
- liver transplant117
- hepatocellular carcinoma61
- alpha 1 foetoprotein increased52
- treatment noncompliance49
- cataract47
- hepatic failure44
- hepatic cirrhosis37
- death35
- lenticular opacities34
- succinylacetone increased33
- vomiting33
- off label use29
- abdominal pain27
- drug ineffective24
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 6 |
| 2005 | 5 |
| 2006 | 11 |
| 2007 | 7 |
| 2008 | 14 |
| 2009 | 18 |
| 2010 | 20 |
| 2011 | 28 |
| 2012 | 37 |
| 2013 | 14 |
| 2014 | 12 |
| 2015 | 30 |
| 2016 | 51 |
| 2017 | 69 |
| 2018 | 99 |
| 2019 | 129 |
| 2020 | 112 |
| 2021 | 40 |
| 2022 | 51 |
| 2023 | 19 |
| 2024 | 18 |
| 2025 | 16 |
| 2026 | 14 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,339 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| succinylacetone increasedSignal | 33 | 282422.8 | 86787.7 | 753,301 |
| amino acid level increasedSignal | 128 | 5343.7 | 4473.8 | 561,553 |
| lenticular opacitiesSignal | 34 | 2166.1 | 1536.7 | 65,874 |
| alpha 1 foetoprotein increasedSignal | 52 | 2022.9 | 1538.2 | 95,548 |
| liver transplantSignal | 117 | 852.9 | 718.9 | 95,550 |
| hepatocellular carcinomaSignal | 61 | 207.4 | 162.8 | 12,230 |
| hepatic cirrhosisSignal | 37 | 50.6 | 36.9 | 1,749 |
| hepatic failureSignal | 44 | 37.5 | 28.1 | 1,526 |
| treatment noncomplianceSignal | 49 | 23.0 | 17.5 | 1,011 |
| cataractSignal | 47 | 20.3 | 15.3 | 843 |
| abdominal painSignal | 27 | 3.0 | 2.1 | 34 |
| vomiting | 33 | 1.8 | 1.3 | 11 |
| death | 35 | 1.0 | 0.8 | 0 |
| off label use | 29 | 0.8 | 0.6 | 1 |
| drug ineffective | 24 | 0.5 | 0.3 | 15 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.